[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649507":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":39,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":45,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Istanbul Saglik Bilimleri University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"PCOS Group",null,"Patients diagnosed with PCOS according to the Rotterdam criteria.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control Group","Women presenting with similar complaints but not meeting Rotterdam diagnostic criteria for PCOS.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"gülden ANATACA","CONTACT","+905059284244","ganataca@yahoo.com",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","GÜLDEN ANATACA","Specialist Physician","100649507","evaluation-of-serum-preptin-levels-in-patients-with-polycystic-ovary-syndrome-100649507",false,"NCT07736079","Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome","Evaluation of Serum Preptin Levels and Their Relationship With Insulin Resistance in Patients With Polycystic Ovary Syndrome","PREPTIN-PCOS","Inclusion Criteria:\n\n* Female participants aged 18-45 years\n* Diagnosis of PCOS according to Rotterdam criteria\n* BMI \\\u003C30 kg\u002Fm²\n* No PCOS treatment during the previous 6 months\n* Not pregnant or breastfeeding\n* No active infection\n* No rheumatologic or inflammatory disease\n* No chronic systemic disease\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>45 years\n* Pregnancy or breastfeeding\n* PCOS treatment within the previous 6 months\n* Active infection\n* Rheumatologic or inflammatory disease\n* Hypertension\n* Diabetes mellitus\n* Chronic kidney disease\n* Refusal to participate","FEMALE","18 Years","45 Years",{"count":37,"type":38},60,"ESTIMATED","12 Weeks","OBSERVATIONAL","Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS.\n\nThe aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.",[43,44],"Polycystic Ovary Syndrome (PCOS)","Insulin Resistance",[46,44,47,48,49],"Polycystic Ovary Syndrome","Preptin","Biomarker","Hyperandrogenism","NOT_YET_RECRUITING","2026-07-28",{"date":53,"type":54},"2026-07-30","ACTUAL",{"date":53,"type":38},{"date":57,"type":38},"2026-09-30",{"name":23,"class":6}]